T-cell Based Immunotherapy for of Melanoma
NCT00937625
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
cyclophosphamide, fludarabine, T-cells, Interleukin-2
Sponsor
Inge Marie Svane